Filing Flows › Kyntra Bio (KYNB) › Q3 2025
Kyntra Bio (KYNB) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Kyntra Bio (KYNB) reported revenue of $1.1M for the third quarter 2025 (Q3 2025), -98% from a year earlier and -20% from the quarter before. Operating margin was -502.9%.
Kyntra Bio, Q3 2025: revenue $1.1M (-98% year over year), operating margin -502.9%, net earnings $201M, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -20% | -98% |
| Operating profit | −$5.4M | — | — |
| Net earnings | $201M | — | — |
| Operating cash flow | −$1.8M | -115% | — |
What changed
Revenue was $1.1M in Q3 2025, down 98% year over year and down 20% from the previous quarter. Drug Product Revenue was the largest line at 89% of revenue. Development and Other Revenue lost $266K year over year (down 69%), 1% of the total change.
Operating costs exceeded revenue by $5.4M, an operating margin of -502.9%. Total costs fell 93% while revenue fell 98%. Net earnings were $200.6M. The effective tax rate was 0.0%. Non-operating items added $206.0M, 103% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.8M. Non-cash charges added back $183K of depreciation and $662K of share-based compensation. Working capital and other items used $203.3M. Capital expenditures of $9K exceeded it, leaving free cash flow of −$1.9M.
Questions
What was Kyntra Bio's revenue in the third quarter 2025?
Kyntra Bio (KYNB) reported revenue of $1.1M for the third quarter 2025 (Q3 2025), -98% from a year earlier and -20% from the quarter before.
Was Kyntra Bio profitable in the third quarter 2025?
Operating loss was $5.4M (-502.9% of revenue) and net earnings $201M.
Source: Kyntra Bio 10-Q on SEC EDGAR.